Latest Breaking News On - Aytu bioscience - Page 14 : comparemela.com

(2) ENGLEWOOD, CO / ACCESSWIRE / December 15, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), ( Aytu or the Company ), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today the closing of its previously announced underwritten public offering of 4,791,667 shares of common stock of the Company, which includes the full exercise of the underwriter s option to purchase an additional 625,000 shares of common stock, at a price to the public of $6.00 per share. H.C. Wainwright & Co. acted as the sole book-running manager for the offering. The gross proceeds to Aytu, before deducting underwriting discounts and commissions and offering expenses, are $28.75 million. The Company intends to use the net proceeds from this offering for working capital and other general corporate purposes.

New yorkUnited statesAytu bioscienceExchange commissionAytu bioscience incInnovus pharmaceuticals incSecurities exchangeHc wainwright coInnovus pharmaceuticalsBeyond humanSecurities actSecurities exchange actபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்பரிமாற்றம் தரகுபுதுமை மருந்துகள் இன்க்